Ricerca
Didattica
Soluzioni
Accedi
IT
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
IGH,
CNRS,
IGH, CNRS
Alboukadel Kassambara has not added Biography.
If you are Alboukadel Kassambara and would like to personalize this page please email our Author Liaison for assistance.
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.
British journal of cancer Apr, 2018 | Pubmed ID: 29500406
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.
Clinical epigenetics Oct, 2018 | Pubmed ID: 30285865
Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway.
Cancer letters Feb, 2019 | Pubmed ID: 30419344
Univ Montpellier
Michel Jourdan1,
Hugues de Boussac1,
Elena Viziteu1,
Alboukadel Kassambara1,
Jérôme Moreaux1,2,3
1IGH, CNRS, Univ Montpellier,
2Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, CHU Montpellier,
3UFR de Médecine, Univ Montpellier
Riservatezza
Condizioni di utilizzo
Politiche
Contattaci
SUGGERISCI JOVE ALLA BIBLIOTECA
Newsletter di JoVE
JoVE Journal
Raccolta di metodi
JoVE Encyclopedia of Experiments
Archivio
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Sportello unico per docenti
Autori
Personale delle biblioteche
Accesso
CHI SIAMO
Copyright © 2024 MyJoVE Corporation. Tutti i diritti riservati